Allison Casey

News
NALIRIFOX Regimen Improves OS in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
11/15/2022
The phase 3 NAPOLI 3 trial demonstrated a statistically significant improvement in OS with the NALIRIFOX regimen vs nab-paclitaxel plus gemcitabine for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
The phase 3 NAPOLI 3 trial demonstrated a statistically significant improvement in OS with the NALIRIFOX regimen vs nab-paclitaxel plus gemcitabine for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
The phase 3 NAPOLI 3 trial...
11/15/2022
Oncology
News
No Benefit From Short-Term Androgen Deprivation Added to Dose-Escalated Radiotherapy for Prostate Cancer
05/24/2023
A phase 3 trial found the addition of short-term androgen deprivation to dose-escalated radiotherapy did not improve the overall survival among patients with intermediate-risk prostate cancer.
A phase 3 trial found the addition of short-term androgen deprivation to dose-escalated radiotherapy did not improve the overall survival among patients with intermediate-risk prostate cancer.
A phase 3 trial found the...
05/24/2023
Oncology
News
Nimotuzumab Improved Survival Outcomes for Patients With KRAS Wild-Type Pancreatic Cancer
10/12/2023
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine...
10/12/2023
Oncology
Conference Coverage
Combining Clinical Biomarkers for Optimal Selection of First-Line Treatment in Metastatic Colorectal Cancer
01/20/2024
According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.
According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.
According to results from the...
01/20/2024
Oncology
Conference Coverage
Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer
05/28/2024
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a...
05/28/2024
Oncology
News
No Benefit from Addition of Atezolizumab to Standard of Care Among Patients With HER2-Positive Breast Cancer
12/08/2023
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a...
12/08/2023
Oncology
News
Study Identifies Patients With Muscle-Invasive Bladder Cancer Who Benefit Most From Neoadjuvant Chemotherapy
06/16/2022
Patients with nonluminal subtype of muscle-invasive bladder cancer experienced improved OS at 3 years when treated with neoadjuvant chemotherapy before undergoing radical cystectomy, according to a recent study.
Patients with nonluminal subtype of muscle-invasive bladder cancer experienced improved OS at 3 years when treated with neoadjuvant chemotherapy before undergoing radical cystectomy, according to a recent study.
Patients with nonluminal subtype...
06/16/2022
Oncology
News
Second-Line Sintilimab Plus Lenvantinib Demonstrates Efficacy, Safety in Intrahepatic Cholangiocarcinoma
08/31/2022
In the second-line treatment setting, sintilimab combined with lenvatinib demonstrated promising efficacy and tolerability among patients with advanced intrahepatic cholangiocarcinoma, according to a multicenter observational study.
In the second-line treatment setting, sintilimab combined with lenvatinib demonstrated promising efficacy and tolerability among patients with advanced intrahepatic cholangiocarcinoma, according to a multicenter observational study.
In the second-line treatment...
08/31/2022
Oncology
News
Cytoreductive Nephrectomy Prolongs OS in Patients With Metastatic Renal Cell Carcinoma Treated With ICIs
11/09/2022
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is associated with longer OS among patients with metastatic renal cell carcinoma who received immune checkpoint inhibitors (ICIs) vs those treated with systemic therapy alone, according to a findings from a...
Cytoreductive nephrectomy is...
11/09/2022
Oncology
News
Association of NECTIN-4 Expression With Enfortumab Vedotin Resistance in Metastatic Urothelial Carcinoma
02/07/2023
Study findings highlight the importance of determining NECTIN-4 receptor status in patients with metastatic urothelial carcinoma before initiation of enfortumab vedotin.
Study findings highlight the importance of determining NECTIN-4 receptor status in patients with metastatic urothelial carcinoma before initiation of enfortumab vedotin.
Study findings highlight the...
02/07/2023
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use